Reviewing Creative Medical Technology (NASDAQ:CELZ) and Cognition Therapeutics (NASDAQ:CGTX)

Cognition Therapeutics (NASDAQ:CGTX) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Cognition Therapeutics and Creative Medical Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-150.93%	-100.82%
Creative Medical Technology	N/A	-63.05%	-60.42%

Valuation & Earnings

This table compares Cognition Therapeutics and Creative Medical Technology”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$25.79 million	($0.97)	-0.44
Creative Medical Technology	$11,000.00	829.51	-$5.29 million	($3.80)	-1.37

Creative Medical Technology has higher revenue and earnings than Cognition Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Cognition Therapeutics has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Creative Medical Technology has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.

Institutional and Insider Ownership

43.3% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are owned by institutional investors. 20.8% of Cognition Therapeutics shares are owned by company insiders. Comparatively, 2.8% of Creative Medical Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Cognition Therapeutics and Creative Medical Technology, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	0	1	5	1	3.00
Creative Medical Technology	0	0	0	0	0.00

Cognition Therapeutics presently has a consensus price target of $8.30, suggesting a potential upside of 1,828.44%. Given Cognition Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Cognition Therapeutics is more favorable than Creative Medical Technology.

Summary

Cognition Therapeutics beats Creative Medical Technology on 8 of the 13 factors compared between the two stocks.

About Cognition Therapeutics

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.